PT1161234E - Tratamento de hipertensao pulmonar por inalacao de prostaglandinas benzindeno - Google Patents

Tratamento de hipertensao pulmonar por inalacao de prostaglandinas benzindeno

Info

Publication number
PT1161234E
PT1161234E PT00920253T PT00920253T PT1161234E PT 1161234 E PT1161234 E PT 1161234E PT 00920253 T PT00920253 T PT 00920253T PT 00920253 T PT00920253 T PT 00920253T PT 1161234 E PT1161234 E PT 1161234E
Authority
PT
Portugal
Prior art keywords
inhalation
pulmonary hypertension
benzindeno
prostaglandines
treatment
Prior art date
Application number
PT00920253T
Other languages
English (en)
Portuguese (pt)
Inventor
Gilles Cloutier
James Crow
Michael Wade
Richard E Parker
James E Loyd
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22417774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1161234(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of PT1161234E publication Critical patent/PT1161234E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00920253T 1999-03-18 2000-03-17 Tratamento de hipertensao pulmonar por inalacao de prostaglandinas benzindeno PT1161234E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12499999P 1999-03-18 1999-03-18

Publications (1)

Publication Number Publication Date
PT1161234E true PT1161234E (pt) 2003-12-31

Family

ID=22417774

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00920253T PT1161234E (pt) 1999-03-18 2000-03-17 Tratamento de hipertensao pulmonar por inalacao de prostaglandinas benzindeno

Country Status (13)

Country Link
US (2) US6521212B1 (OSRAM)
EP (1) EP1161234B1 (OSRAM)
JP (2) JP4819224B2 (OSRAM)
KR (1) KR100750384B1 (OSRAM)
CN (1) CN1196479C (OSRAM)
AT (1) ATE245979T1 (OSRAM)
AU (1) AU4082700A (OSRAM)
CA (1) CA2365890C (OSRAM)
DE (1) DE60004181T2 (OSRAM)
DK (1) DK1161234T3 (OSRAM)
ES (1) ES2203449T3 (OSRAM)
PT (1) PT1161234E (OSRAM)
WO (1) WO2000054758A2 (OSRAM)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
DE10163697A1 (de) * 2001-12-21 2003-07-03 Studiengesellschaft Kohle Mbh Reversible Speicherung von Wasserstoff mit Hilfe von dotierten Alkalimetallaluminiumhydriden
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
CN101265226B (zh) 2003-05-22 2013-04-24 联合治疗公司 化合物和释放前列环素类似物的方法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
DE602004022982D1 (de) * 2003-12-16 2009-10-15 United Therapeutics Corp Verwendung von treprostinil zur verbesserung der nierenfunktion
US20090124697A1 (en) * 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CA2549724C (en) * 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
ATE462427T1 (de) * 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US20100130500A1 (en) * 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
AU2006321942A1 (en) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
KR101390579B1 (ko) * 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 정량 흡입기를 사용한 트레프로스티닐 투여
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
KR20160048222A (ko) 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
ES2575565T3 (es) * 2008-05-08 2016-06-29 United Therapeutics Corporation Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
WO2010036798A1 (en) * 2008-09-25 2010-04-01 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
KR101544246B1 (ko) * 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
EP3108888B1 (en) 2010-03-15 2020-02-12 United Therapeutics Corporation Treatment for pulmonary hypertension
CA2777070C (en) 2010-06-03 2019-11-05 United Therapeutics Corporation Treprostinil production
EP2681204B1 (en) 2011-03-02 2016-04-27 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
CN109608326A (zh) 2013-03-15 2019-04-12 联合治疗公司 曲前列环素的盐
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
EP3808731A1 (en) 2013-10-25 2021-04-21 Insmed Incorporated Prostacyclin compounds
US20170095432A1 (en) 2014-06-13 2017-04-06 United Therapeutics Corporation Treprostinil formulations
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2016088119A1 (en) 2014-12-03 2016-06-09 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
RU2593016C2 (ru) * 2014-12-15 2016-07-27 Федеральное государственное бюджетное учреждение науки Институт теоретической и прикладной механики им. С.А. Христиановича Сибирского отделения Российской академии наук (ИТПМ СО РАН) Способ лечения артериальной гипертензии путем ингаляционного введения аэрозоля гипотензивного препарата
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
CA3112986C (en) 2018-09-18 2024-06-18 Eli Lilly And Company Erbumine salt of treprostinil
JP7431837B2 (ja) 2018-10-05 2024-02-15 ゼノセラピューティクス インコーポレイテッド 異種移植製品及び異種移植方法
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
US11458098B2 (en) 2019-04-29 2022-10-04 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
US11339110B2 (en) 2019-12-19 2022-05-24 Chirogate International Inc. Efficient crystallization process for preparing ultrapure Treprostinil and crystal prepared therefrom
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
WO2021252446A1 (en) 2020-06-09 2021-12-16 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
US11447440B2 (en) 2020-10-29 2022-09-20 Chirogate International Inc. Treprostinil monohydrate crystals and methods for preparation thereof
JP2023553989A (ja) 2020-12-14 2023-12-26 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグで疾患を治療する方法
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
KR20240141319A (ko) 2022-02-08 2024-09-26 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 일로프로스트 조합 치료 요법
EP4516297A1 (en) 2022-04-29 2025-03-05 Zhaoke Pharmaceutical (Guangzhou) Co., Ltd Treprostinil soft mist inhalant
EP4651879A1 (en) 2023-01-18 2025-11-26 United Therapeutics Corporation Treatment of pulmonary arterial hypertension
KR20250139830A (ko) 2023-01-19 2025-09-23 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 유사체

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338457A (en) * 1980-02-28 1982-07-06 The Upjohn Company Composition and process
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4306076A (en) * 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
JPS5795920A (en) * 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4349689A (en) * 1980-12-22 1982-09-14 The Upjohn Company Methano carbacyclin analogs
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
ZA851337B (en) * 1984-03-08 1985-10-30 Upjohn Co Interphenylene carbacyclin derivatives
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
AU623147B2 (en) * 1988-06-17 1992-05-07 Wellcome Foundation Limited, The Compounds for use in medicine
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
CN1142781C (zh) * 1997-11-14 2004-03-24 联合治疗公司 9－脱氧－2′,9－α－亚甲基－3－氧杂－4,5,6－三去甲－3,7－(1′,3′－间亚苯基)－13,14－二氢－前列腺素F1在治疗外周血管疾病中的用途
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation

Also Published As

Publication number Publication date
KR20010108352A (ko) 2001-12-07
EP1161234B1 (en) 2003-07-30
ATE245979T1 (de) 2003-08-15
DK1161234T3 (da) 2003-11-24
KR100750384B1 (ko) 2007-08-17
ES2203449T3 (es) 2004-04-16
CA2365890A1 (en) 2000-09-21
CN1196479C (zh) 2005-04-13
US6521212B1 (en) 2003-02-18
DE60004181T2 (de) 2004-04-15
US20030053958A1 (en) 2003-03-20
CA2365890C (en) 2010-09-21
US6756033B2 (en) 2004-06-29
CN1379665A (zh) 2002-11-13
DE60004181D1 (de) 2003-09-04
JP2002539154A (ja) 2002-11-19
WO2000054758A2 (en) 2000-09-21
AU4082700A (en) 2000-10-04
JP4819224B2 (ja) 2011-11-24
EP1161234A2 (en) 2001-12-12
WO2000054758A3 (en) 2001-02-08
JP2011201907A (ja) 2011-10-13

Similar Documents

Publication Publication Date Title
PT1161234E (pt) Tratamento de hipertensao pulmonar por inalacao de prostaglandinas benzindeno
NO20044699L (no) Vaginalpleiesammensetning
IT1306681B1 (it) Struttura di capo traspirante da indossare per migliorare il comfortdel corpo umano.
DE60115842D1 (de) Ventilanordnung
DE60018797D1 (de) Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
WO2002060389A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
NZ507203A (en) Use of dexmedetomidine for ICU sedation
AU3258801A (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
PT813416E (pt) Reducao do volume de enfarte usando citicolina
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
NO20002218D0 (no) Anvendelse av mirtazepin for behandling av søvnapne
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
CR6614A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural gaba
SE9902597D0 (sv) New use
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
HRP20041150A2 (en) Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
MXPA05010068A (es) Promocion de la angiogenesis por composiciones de prostaglandina y metodos.
SE0004462D0 (sv) Novel method and use